We recently reported on the activity of cationic amphiphiles in inhibiting TLR4 activation and subsequent production of inflammatory cytokines in cells and in animal models. Starting from the assumption that opportunely designed cationic amphiphiles can behave as CD14/MD-2 ligands and therefore modulate the TLR4 signaling, we present here a panel of amphiphilic guanidinocalixarenes whose structure was computationally optimized to dock into MD-2 and CD14 binding sites. Some of these calixarenes were active in inhibiting, in a dose-dependent way, the LPS-stimulated TLR4 activation and TLR4-dependent cytokine production in human and mouse cells. Moreover, guanidinocalixarenes also inhibited TLR4 signaling when TLR4 was activated by a non-LPS stimulus, the plant lectin PHA. While the activity of guanidinocalixarenes in inhibiting LPS toxic action has previously been related to their capacity to bind LPS, we suggest a direct antagonist effect of calixarenes on TLR4/MD-2 dimerization, pointing at the calixarene moiety as a potential scaffold for the development of new TLR4-directed therapeutics.
Sestito, S., Facchini, F., Morbioli, I., Billod, J., Martin Santamaria, S., Casnati, A., et al. (2017). Amphiphilic Guanidinocalixarenes Inhibit Lipopolysaccharide (LPS)-and Lectin-Stimulated Toll-like Receptor 4 (TLR4) Signaling. JOURNAL OF MEDICINAL CHEMISTRY, 60(12), 4882-4892 [10.1021/acs.jmedchem.7b00095].
Amphiphilic Guanidinocalixarenes Inhibit Lipopolysaccharide (LPS)-and Lectin-Stimulated Toll-like Receptor 4 (TLR4) Signaling
SESTITO, STEFANIA ENZAPrimo
;FACCHINI, FABIO ALESSANDROSecondo
;PERI, FRANCESCO
Ultimo
2017
Abstract
We recently reported on the activity of cationic amphiphiles in inhibiting TLR4 activation and subsequent production of inflammatory cytokines in cells and in animal models. Starting from the assumption that opportunely designed cationic amphiphiles can behave as CD14/MD-2 ligands and therefore modulate the TLR4 signaling, we present here a panel of amphiphilic guanidinocalixarenes whose structure was computationally optimized to dock into MD-2 and CD14 binding sites. Some of these calixarenes were active in inhibiting, in a dose-dependent way, the LPS-stimulated TLR4 activation and TLR4-dependent cytokine production in human and mouse cells. Moreover, guanidinocalixarenes also inhibited TLR4 signaling when TLR4 was activated by a non-LPS stimulus, the plant lectin PHA. While the activity of guanidinocalixarenes in inhibiting LPS toxic action has previously been related to their capacity to bind LPS, we suggest a direct antagonist effect of calixarenes on TLR4/MD-2 dimerization, pointing at the calixarene moiety as a potential scaffold for the development of new TLR4-directed therapeutics.File | Dimensione | Formato | |
---|---|---|---|
Sestito-2017-J Med Chem-VoR.pdf
Solo gestori archivio
Descrizione: Article
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Tutti i diritti riservati
Dimensione
4.77 MB
Formato
Adobe PDF
|
4.77 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Sestito-2017-J Med Chem-AAM.pdf
accesso aperto
Descrizione: Article
Tipologia di allegato:
Author’s Accepted Manuscript, AAM (Post-print)
Licenza:
Altro
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.